These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33955638)

  • 1. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A.
    Mannucci PM; Cortesi PA; Di Minno MND; Sanò M; Mantovani LG; Di Minno G
    Haemophilia; 2021 Jul; 27(4):e422-e433. PubMed ID: 33955638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
    Schep SJ; Fischer K; Boes M; Schutgens REG
    Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining extended half-life rFVIII-A critical review of the evidence.
    Mahlangu J; Young G; Hermans C; Blanchette V; Berntorp E; Santagostino E
    Haemophilia; 2018 May; 24(3):348-358. PubMed ID: 29633467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
    Kim HK; Peral C; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):315-320. PubMed ID: 32597317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
    Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
    Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
    Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review.
    Ay C; Napolitano M; Hassoun A; Tomic R; Martin C; Seifert W; Pinachyan K; Oldenburg J
    Haemophilia; 2024 May; 30(3):577-588. PubMed ID: 38549463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products.
    Chhabra A; Fogarty PF; Tortella BJ; Spurden D; Alvir J; McDonald M; Hodge J; Pleil AM
    Manag Care; 2018 Oct; 27(10):39-50. PubMed ID: 30309448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
    Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
    J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.